Lecture Notes

**Lecture Coverage:**
- Strategies for Vaccine Design
- Vaccine Types

---
#### **Strategies for Vaccine Design**
**Principle**
-  Mimic Infection Process & Induce Adaptive Immunoresponse
	- Active Immunization: Generates Memory Response
-  Without Causing Damage

**Considerations**
- Nature of Pathogen
	- Variability of Pathogen
- Route of Infection / Vaccine Administration
	- Mucosal V.S. Systemic
- Protection & Duration
	- Boosters amount
	- Homologous / Heterologous


#### **Vaccine Types**

|                                   Vaccine Type                                    | Advantages                                                          | Disadvantages                                                                                           | Example                                                                                             |
| :-------------------------------------------------------------------------------: | ------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------- | --------------------------------------------------------------------------------------------------- |
|                                  Live-Attenuated                                  | High Potency & Duration                                             | Required Cold Storage<br>Virulence from Mutation                                                        | Measles<br><abbr Title="Tuberculosis">TB</abbr> <abbr Title="Bacillus Calmette-Guerin">(BCG)</abbr> |
|                             <br>Inactivated / Killed                              | Stable & Safer<br>Cold Storage not required                         | Lower Strength<br>Requires Boosters                                                                     | Influenza<br>Hepatitis A<br>Zika                                                                    |
| <abbr Title="Antigen encoded into harmless virus">Recombinant Viral Vector</abbr> | High Potency                                                        | <abbr Title="Reduced effectiveness to those exposed to vector before">Anti-viral Vector Immunity</abbr> | Ebola<br>COVID-19 (AZ)                                                                              |
|                               <br>Subunit (Antigen)                               | No Risk                                                             | Less likely high duration<br>Requires <abbr Title="Immunoresponse boosting substances">Adjuvants</abbr> | Protein-based<br>Toxoid<br>Polysaccharide                                                           |
|                                       mRNA                                        | High Potency<br>Rapid & Cost-effective                              | Poor Intracellular Delivery<br>Unstable                                                                 | COVID (Pfizer)                                                                                      |
|                                 DNA (in Plasmids)                                 | High Potency<br>Rapid & Cost-effective<br>Cold Storage not required | Need electroporation<br>Requires Boosters                                                               |                                                                                                     |
